Imperial College London
Alternate

DrJonathanBaker

Faculty of Medicine, National Heart & Lung Institute

Honorary Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 7790jonathan.baker

 
 
//

Location

 

223Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Baker:2021:10.2147/COPD.S266394,
author = {Baker, JR and Donnelly, LE},
doi = {10.2147/COPD.S266394},
journal = {The International Journal of Chronic Obstructive Pulmonary Disease},
pages = {2227--2242},
title = {Leukocyte function in COPD: clinical relevance and potential for drug therapy.},
url = {http://dx.doi.org/10.2147/COPD.S266394},
volume = {16},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Chronic obstructive pulmonary disease (COPD) is a progressive lung condition affecting 10% of the global population over 45 years. Currently, there are no disease-modifying treatments, with current therapies treating only the symptoms of the disease. COPD is an inflammatory disease, with a high infiltration of leukocytes being found within the lung of COPD patients. These leukocytes, if not kept in check, damage the lung, leading to the pathophysiology associated with the disease. In this review, we focus on the main leukocytes found within the COPD lung, describing how the release of chemokines from the damaged epithelial lining recruits these cells into the lung. Once present, these cells become active and may be driven towards a more pro-inflammatory phenotype. These cells release their own subtypes of inflammatory mediators, growth factors and proteases which can all lead to airway remodeling, mucus hypersecretion and emphysema. Finally, we describe some of the current therapies and potential new targets that could be utilized to target aberrant leukocyte function in the COPD lung. Here, we focus on old therapies such as statins and corticosteroids, but also look at the emerging field of biologics describing those which have been tested in COPD already and potential new monoclonal antibodies which are under review.
AU  - Baker,JR
AU  - Donnelly,LE
DO  - 10.2147/COPD.S266394
EP  - 2242
PY  - 2021///
SN  - 1176-9106
SP  - 2227
TI  - Leukocyte function in COPD: clinical relevance and potential for drug therapy.
T2  - The International Journal of Chronic Obstructive Pulmonary Disease
UR  - http://dx.doi.org/10.2147/COPD.S266394
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34354348
UR  - https://www.dovepress.com/leukocyte-function-in-copd-clinical-relevance-and-potential-for-drug-t-peer-reviewed-fulltext-article-COPD
UR  - http://hdl.handle.net/10044/1/91018
VL  - 16
ER  -
Download